Ovarian Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Ovarian Serous Adenocarcinoma (24)

›

BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days (New C3) BSI 201 Sensitive : C3 Oncologist - 3d	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days BSI 201 Sensitive : C3 Oncologist - 3 days - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days (New C3) BSI 201 Sensitive : C3 Oncologist - 3d	BSI 201 Sensitive: C3 – Early Trials Oncologist - 3 days BSI 201 Sensitive : C3 Oncologist - 3 days - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week (New C3) olaparib Sensitive : A1 Anticancer Res - 1wk	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week olaparib Sensitive : A1 Anticancer Res - 1 week - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week (New C3) olaparib Sensitive : A1 Anticancer Res - 1wk	olaparib Sensitive: A1 - Approval Anticancer Res - 1 week olaparib Sensitive : A1 Anticancer Res - 1 week - (New C3)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks (New B) bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval Eur J Cancer - 3 weeks bevacizumab + olaparib Sensitive : A1 Eur J Cancer - 3 weeks - (New B)
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + pegylated liposomal doxorubicin Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	leucovorin calcium Sensitive: A2 - Guideline leucovorin calcium Sensitive : A2	leucovorin calcium Sensitive: A2 - Guideline leucovorin calcium Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2	oxaliplatin Sensitive: A2 - Guideline oxaliplatin Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2	exemestane Sensitive: A2 - Guideline exemestane Sensitive : A2

Ovarian Cancer

Associations(460)

Associations
(460)